The transforming growth factor β (TGFβ) superfamily of cytokines elicit diverse biological responses by interacting with two distinct, but structurally related transmembrane receptor serine kinases (type I and type II). The binding of these dimeric ligands to the type II receptor is the first event in transmembrane signaling for this family. Here we report the 1.5 Å resolution crystal structure of the extracellular ligand-binding domain of the type II activin receptor (ActRII-ECD), which reveals a fold similar to that of a class of toxins known as three-finger toxins. This fold is primarily dictated by disulfide bonds formed by eight conserved cysteines, with a characteristic spacing, and thus is likely to be shared by most of the type I and II receptors for the TGFβ family. Sequence comparison with an evolutionarily distant activin binding-protein identifies several conserved residues, including two hydrophobic clusters that may form binding surfaces for activin and the type I receptor.
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Protein Data Bank
Kessler, D.S. & Melton, D.A. Science 266, 596–604 (1994).
Vale, W., Hseuh, A., Rivier, C. & Yu, J. In Peptide growth factors and their receptors (eds Sporn, M. & Roberts, A.) 211– 248 (Springer-Verlag, Berlin; 1990).
Vale, W. et al. Nature 321, 776–779 (1986).
Mathews, L.S. & Vale, W.W. Cell 65, 973 –982 (1991).
Mathews, L.S. & Vale, W.W. Receptor 3, 173–181 (1993).
Wrana, J.L., Attisano, L., Wieser, R., Ventura, F. & Massague, J. Nature 370, 341– 347 (1994).
Attisano, L., Wrana, J.L., Montalvo, E. & Massague, J. Mol. Cell. Biol. 16, 1066–1073 (1996).
Lebrun, J.J. & Vale, W.W. Mol. Cell. Biol. 17, 1682–1691 (1997).
Donaldson, C.J., Vaughan, J.M., Corrigan, A.C., Fischer, W.H. & Vale, W.W. Endocrinology in the press.
Greenwald, J. et al. Biochemistry, 37, 16711– 16718 (1998).
Ruberte, E., Marty, T., Nellen, D., Affolter, M. & Basler, K. Cell 80, 889– 897 (1995).
Childs, S.R., Wrana, J.L., Arora, K., Attisano, L., O'Connor, M.B. & Massague, J. Proc. Natl. Acad. Sci. USA 90, 9475– 9479 (1993).
Rees, B. & Bilwes, A. Chem. Res. Toxicol. 6, 385–406 (1993).
McDonald, N.Q. & Hendrickson, W.A. Cell 73, 421–424 (1993).
Schlunegger, M.P. & Grütter, M.G. Nature 358, 430–434 (1992).
Daopin, S., Piez, K.A., Ogawa, Y. & Davies, D.R. Science 257, 369–373 (1992).
Young, L., Jernigan, R.L. & Covell, D.G. Prot. Sci. 3, 717– 729 (1994).
Clackson, T. & Wells, J.A. Science 267, 383–386 (1995).
Janin, J. & Chothia, C. J. Biol. Chem. 265, 16027–16030 (1990).
Yeates, T.O. Meth. Enz. 276, 344–358 (1997).
Otwinowski, Z. in Proceedings of the CCP4 study weekend (eds Sawyer, L., Isaacs, N. & Burley, S.) 56–62 (Daresbury Laboratory, Warrington, UK; 1993).
Collaborative Computational Project No. 4. Acta Crystallogr. D 50, 760–776 (1994).
Kleywegt, G. & Jones, T.A. In From first map to final model (eds Bailey, S., Hubbard, R. & Waller, D.) 59– 66 (Daresbury Laboratory, Warrington, UK; 1994).
Perrakis, A., Sixma, T.K., Wilson, K. & Lamzin, V.S. Acta Crystallogr. D 53, 448–455 (1997).
Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. Acta Crystallogr. A 47, 100–119 (1991).
Bilwes, A., Rees, B., Moras, D., Menez, R. & Menez, A. J. Mol. Biol. 239, 122– 136 (1994).
Evans, S.V. J. Mol. Graphics 11, 134–138 (1993).
Barton, G.J. Prot. Engng. 6, 37–40 (1993).
Nicholls, A., Sharp, K.A. & Honig, B. Proteins Struct. Funct. Genet. 11, 281–296 (1991).
We thank G. Louie, R. Robinson and T. Hunter for helpful discussions and comments on the manuscript; H. Bellamy at SSRL and T. Earnest at ALS for help with data collection. SSRL and ALS are operated by the Department of Energy, Office of Basic Energy Sciences. The SSRL Biotechnology Program is supported by the National Institutes of Health, National Center for Research Resources, Biomedical Technology Program, and by the Department of Energy, Office of Biological and Environmental Research. J.G. is a Howard Hughes Medical Institute Predoctoral Fellow and Markey Fellow. S.C. is a recipient of a Klingenstein Fellowship Award in Neuroscience. This work was supported by a grant from the NIH.Correspondence should be addressed to S.C. email@example.com
About this article
Cite this article
Greenwald, J., Fischer, W., Vale, W. et al. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase.. Nat Struct Mol Biol 6, 18–22 (1999). https://doi.org/10.1038/4887
GP73, a novel TGF-β target gene, provides selective regulation on Smad and non-Smad signaling pathways
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2019)
Experimental Biology and Medicine (2019)
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
Proceedings of the National Academy of Sciences (2017)
Molecular characterization of Activin Receptor Type IIA and its expression during gonadal maturation and growth stages in rohu carp
Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology (2017)
The Journal of Pathology (2017)